Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages 2735-2736

  Sorscher, Steven M ^a   Lockhart, Albert Craig ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; RAS PROTEIN; ZOLEDRONIC ACID;

CANCER SURVIVAL; CLINICAL TRIAL; GENE MUTATION; HUMAN; LETTER; MULTIPLE MYELOMA; OSTEOCLAST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PRENYLATION; PROTEIN PROCESSING; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BIOPSY; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MULTIPLE MYELOMA; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND; RAS PROTEINS; TREATMENT OUTCOME;

EID: 79960119562     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.8333     Document Type: Letter

References (7)

1. Henry DH, Costa L, Goldwasser F, et al: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132, 2011
2. Green JR: Bisphosphonates: Preclinical review. Oncologist 9:3-13, 2004 (suppl 4)
3. Riddle MK, Lockhart AC, Sorscher SM: Complete radiographic response to zoledronic acid therapy in a patient with bony metastatic urothelial carcinoma: A case report. World J Oncol 1:208-209, 2010
4. Miwa S, Mizokami A, Konaka H, et al: A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy. Jpn J Clin Oncol 39:745-750, 2009
5. Zaghloul MS, Boutrus R, El-Hossieny H, et al: A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15:382-389, 2010
6. Morgan GJ, Davies FE, Gregory WM, et al: First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 376:1989-1999, 2010
7. Liu P, Leong T, Quam L, et al: Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88:2699-2706, 1996 (Pubitemid 26327523)